Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA grants triheptanoin orphan drug status for GLUT-1 deficiency syndrome

Oct. 30, 2014

Scientists identify miR-34a as suppressor of osteoclastogenesis and bone resorption

Oct. 29, 2014

CHMP recommends approval of Duavive

Oct. 28, 2014

Novel GPR120 modulators divulged by Bristol-Myers Squibb

Oct. 27, 2014

ProteoTech given FDA orphan drug status for AL amyloidosis candidate

Oct. 27, 2014

FDA extends PDUFA action date for Natpara BLA

Oct. 24, 2014

Oramed releases topline results from phase IIa study of oral insulin in type 1 diabetes

Oct. 24, 2014

Forendo Pharma closes financing round to develop a novel therapy for endometriosis

Oct. 24, 2014

Repros Therapeutics reports results from long-term safety study of Androxal

Oct. 23, 2014

Bristol-Myers Squibb reports new FFAR4 modulators

Oct. 23, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...